Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients
Recruiting · NCT06615752 · Interventional (participants receive a specific treatment) · Lead sponsor: Charles Drew University of Medicine and Science
View the official record on ClinicalTrials.gov →Interventions studied
Placebo + docetaxelgreen tea and quercetin + docetaxel
What this trial is about
The goal of this clinical trial is to find out if taking natural products green tea and quercetin along with docetaxel chemotherapy improves the therapy of advanced prostate cancer, i.e., metastatic castration-resistant prostate cancer (mCRPC). It will also learn about the safety of this combination. Researchers will compare green tea plus quercetin to a placebo (a look-alike substance that contains no drug) in combination with docetaxel to see if green tea and quercetin works to improve the therapeutic effect of docetaxel.
Who can take part
Age range
18 Years and older
Sex
Male
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 1, Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Signed and dated informed consent form and HIPPA (Health Insurance Portability and Accountability Act) authorization.
- Stated willingness to comply with all study procedures and availability for the duration of the study.
- Male patients 18 years or older
- Diagnosed with metastatic prostate cancer
- History of confirmed progressive disease with concurrent use of medical castration (e.g. luteinizing hormone-releasing hormone analogue), or surgical castration
- Confirmed progressive disease with concurrent use of enzalutamide, apalutamide, darolutamide, and/or abiraterone acetate
- Clinical decision to start doc infusion with prednisone treatment
- Adequate bone marrow function (absolute neutrophil count (ANC) more than1500 cells/mm³, platelet count more than 100,000 cells/mm³)
- Adequate liver function (total bilirubin less than upper limit of normal (ULN), alanine aminotransferase (ALT) less than 1.5 x ULN, aspartate aminotransferase (AST) less than 1.5 x ULN)
- Adequate renal function (serum creatinine level within normal limits)
- At least a 6-month or greater life expectancy
- Willing to stop consuming tea or tea-containing products and quercetin supplements throughout the entire intervention period except for the green tea extract and quercetin provided during study intervention
Exclusion criteria
- Prior treatment of chemotherapy and/or radiotherapy for metastatic disease
- Any comorbid condition that would preclude the administration of docetaxel/prednisone
- Ongoing alcohol abuse
- Significant medical or psychiatric conditions that would make the patient a poor protocol candidate
- Prior allergic reaction to tea, tea products or quercetin supplements
- Allergies to multiple food items or nutritional supplements
Where it is running
1 location listed across 1 US state.
- Charles R. Drew University of Medicine and Science - Los Angeles, California, United States